In yet another delay for the F-star buyout, CFIUS extends review of 'national security risks'
F-star Therapeutics $FSTX has been forced to extend its long streak of delays for the proposed takeover deal by China’s Sino Biopharm, raising the risk the buyout may not get a green light as a US committee tasked with reviewing foreign investments raises “national security concerns.”
On Monday the biotech filed notice of the Committee on Foreign Investment in the United States’ decision that it is extending its review by 45 days, which puts it on track to make a decision by the end of January — unless they decide to delay it again. The biotechs then extended their buyout pact to the end of December, the latest in a long string of delays since they announced the deal last June.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it's free.